Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ESPR | US
0.34
18.68%
Healthcare
Biotechnology
30/06/2024
04/10/2024
2.16
1.98
2.17
1.94
Esperion Therapeutics Inc. a pharmaceutical company develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral small molecule PCSK9 inhibitor program. Esperion Therapeutics Inc. was incorporated in 2008 and is headquartered in Ann Arbor Michigan.
View LessStrength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
120.0%1 month
95.7%3 months
74.7%6 months
84.7%-
1.30
98.42
-1.62
1.58
-3.86
1.47
-4.78
4.99M
423.85M
423.85M
-
3.49
-
186.30
-260.79
10.84
19.46
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.59
Range1M
0.59
Range3M
1.19
Rel. volume
1.45
Price X volume
9.75M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Ginkgo Bioworks Holdings Inc. | DNA | Biotechnology | 8.33 | 462.94M | 8.04% | n/a | 54.29% |
EyePoint Pharmaceuticals Inc | EYPT | Biotechnology | 8.63 | 461.86M | 5.12% | n/a | 10.20% |
Quanterix Corporation | QTRX | Biotechnology | 11.9 | 456.71M | -4.80% | n/a | 11.75% |
Mind Medicine (MindMed) Inc. Subordinate Voting Shares | MNMD | Biotechnology | 5.57 | 456.67M | 0.36% | n/a | 12.00% |
Alector Inc | ALEC | Biotechnology | 4.62 | 449.62M | 2.67% | n/a | 23.98% |
Xeris Pharmaceuticals Inc | XERS | Biotechnology | 2.98 | 444.02M | 2.41% | n/a | -1398.96% |
Absci Corporation Common Stock | ABSI | Biotechnology | 3.88 | 440.60M | 2.11% | n/a | 6.02% |
Foghorn Therapeutics Inc | FHTX | Biotechnology | 7.83 | 433.22M | -6.00% | n/a | -285.69% |
Verve Therapeutics Inc. Common Stock | VERV | Biotechnology | 5 | 423.12M | 4.17% | n/a | 13.27% |
Taysha Gene Therapies Inc | TSHA | Biotechnology | 2.01 | 417.91M | -1.95% | n/a | 53.02% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.02 | 57.65M | -4.67% | n/a | 268.43% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -3.86 | 0.76 | Cheaper |
Ent. to Revenue | 1.47 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 98.42 | 14.10 | Expensive |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 74.69 | 74.67 | Par |
Debt to Equity | -1.62 | -1.82 | Cheaper |
Debt to Assets | 1.58 | 0.26 | Expensive |
Market Cap | 423.85M | 3.73B | Emerging |